BR112013027554A2 - "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" - Google Patents
"usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"Info
- Publication number
- BR112013027554A2 BR112013027554A2 BR112013027554A BR112013027554A BR112013027554A2 BR 112013027554 A2 BR112013027554 A2 BR 112013027554A2 BR 112013027554 A BR112013027554 A BR 112013027554A BR 112013027554 A BR112013027554 A BR 112013027554A BR 112013027554 A2 BR112013027554 A2 BR 112013027554A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- autism
- huntington
- disorders
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
métodos de tratar doença de alzheimer, doença de huntington, autismo, ou outros distúrbios a descrição se refere, pelo menos em parte, aos métodos de tratar autismo em um paciente com necessidade do mesmo, administrando uma dose eficaz de um componente descrito, por exemplo, um agonista parcial do sitio de glicina receptor de nmda.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161479593P | 2011-04-27 | 2011-04-27 | |
US201161527744P | 2011-08-26 | 2011-08-26 | |
PCT/US2012/035547 WO2012149389A2 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013027554A2 true BR112013027554A2 (pt) | 2016-09-06 |
Family
ID=47073094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013027554A BR112013027554A2 (pt) | 2011-04-27 | 2012-04-27 | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" |
Country Status (13)
Country | Link |
---|---|
US (4) | US20140107037A1 (pt) |
EP (2) | EP2701721A4 (pt) |
JP (1) | JP6035326B2 (pt) |
KR (5) | KR20190037359A (pt) |
CN (2) | CN103974712A (pt) |
AU (1) | AU2012249397B2 (pt) |
BR (1) | BR112013027554A2 (pt) |
CA (1) | CA2834286A1 (pt) |
EA (2) | EA029999B1 (pt) |
HK (1) | HK1258231A1 (pt) |
MX (1) | MX357761B (pt) |
SG (2) | SG194230A1 (pt) |
WO (1) | WO2012149389A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010033757A1 (en) | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
SG10201501050RA (en) | 2010-02-11 | 2015-04-29 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
JP6531042B2 (ja) | 2013-01-29 | 2019-06-12 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
BR112015018092A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos |
JP2016506958A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
BR112015018094A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
EA201591404A1 (ru) | 2013-01-29 | 2016-01-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
KR20160077153A (ko) | 2013-10-28 | 2016-07-01 | 노렉스, 인크. | Nmda 수용체 조절인자 및 이들의 전구약물, 염, 그리고 용도 |
CA2933372A1 (en) * | 2013-12-13 | 2015-06-18 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
RU2721401C2 (ru) * | 2014-06-23 | 2020-05-19 | Нортвестерн Юниверсити | Способы лечения или облегчения мигрени |
EP3362080A1 (en) * | 2015-10-16 | 2018-08-22 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US11028095B2 (en) | 2016-08-01 | 2021-06-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
EA201990428A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
JP2019527233A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタムnmda受容体修飾因子及びその使用 |
KR102503590B1 (ko) | 2016-08-01 | 2023-02-24 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
KR20200115611A (ko) | 2018-01-31 | 2020-10-07 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
KR102415692B1 (ko) | 2020-09-01 | 2022-07-05 | 건국대학교 글로컬산학협력단 | 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
ES2428313T3 (es) * | 2005-03-24 | 2013-11-07 | Emory University | Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente |
US9783851B2 (en) * | 2008-02-20 | 2017-10-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
PT2485751E (pt) * | 2009-10-05 | 2014-09-01 | Univ Northwestern | Glyx-13 para uso num método para tratar depressão refratária |
-
2012
- 2012-04-27 MX MX2013012526A patent/MX357761B/es active IP Right Grant
- 2012-04-27 SG SG2013079603A patent/SG194230A1/en unknown
- 2012-04-27 AU AU2012249397A patent/AU2012249397B2/en not_active Ceased
- 2012-04-27 EA EA201391581A patent/EA029999B1/ru unknown
- 2012-04-27 SG SG10202010665YA patent/SG10202010665YA/en unknown
- 2012-04-27 EA EA201790653A patent/EA201790653A1/ru unknown
- 2012-04-27 JP JP2014508130A patent/JP6035326B2/ja not_active Expired - Fee Related
- 2012-04-27 CN CN201280027349.3A patent/CN103974712A/zh active Pending
- 2012-04-27 US US14/114,376 patent/US20140107037A1/en not_active Abandoned
- 2012-04-27 WO PCT/US2012/035547 patent/WO2012149389A2/en active Application Filing
- 2012-04-27 CA CA2834286A patent/CA2834286A1/en not_active Abandoned
- 2012-04-27 KR KR1020197008907A patent/KR20190037359A/ko not_active Application Discontinuation
- 2012-04-27 EP EP12777016.2A patent/EP2701721A4/en not_active Ceased
- 2012-04-27 EP EP20151676.2A patent/EP3679931A3/en not_active Withdrawn
- 2012-04-27 KR KR1020187022910A patent/KR20180095096A/ko not_active Application Discontinuation
- 2012-04-27 KR KR1020207011211A patent/KR20200043534A/ko active Application Filing
- 2012-04-27 BR BR112013027554A patent/BR112013027554A2/pt not_active Application Discontinuation
- 2012-04-27 KR KR1020137031028A patent/KR20140043078A/ko active Application Filing
- 2012-04-27 CN CN201711451914.XA patent/CN108283712A/zh active Pending
- 2012-04-27 KR KR1020217011613A patent/KR20210046843A/ko not_active Application Discontinuation
-
2016
- 2016-04-14 US US15/098,985 patent/US20170049845A1/en not_active Abandoned
-
2018
- 2018-10-23 US US16/168,242 patent/US20190209642A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100591.2A patent/HK1258231A1/zh unknown
-
2020
- 2020-05-05 US US16/867,324 patent/US20210169964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG194230A1 (en) | 2013-12-30 |
US20210169964A1 (en) | 2021-06-10 |
AU2012249397A1 (en) | 2013-11-07 |
WO2012149389A2 (en) | 2012-11-01 |
MX357761B (es) | 2018-07-23 |
CN103974712A (zh) | 2014-08-06 |
EP3679931A3 (en) | 2020-10-14 |
EA201391581A1 (ru) | 2014-05-30 |
US20140107037A1 (en) | 2014-04-17 |
KR20190037359A (ko) | 2019-04-05 |
JP6035326B2 (ja) | 2016-11-30 |
EA029999B1 (ru) | 2018-06-29 |
US20170049845A1 (en) | 2017-02-23 |
EP2701721A2 (en) | 2014-03-05 |
WO2012149389A3 (en) | 2014-05-08 |
KR20180095096A (ko) | 2018-08-24 |
KR20140043078A (ko) | 2014-04-08 |
HK1258231A1 (zh) | 2019-11-08 |
AU2012249397B2 (en) | 2017-03-30 |
KR20210046843A (ko) | 2021-04-28 |
EA201790653A1 (ru) | 2017-07-31 |
CN108283712A (zh) | 2018-07-17 |
CA2834286A1 (en) | 2012-11-01 |
KR20200043534A (ko) | 2020-04-27 |
EP2701721A4 (en) | 2015-12-16 |
SG10202010665YA (en) | 2020-11-27 |
MX2013012526A (es) | 2014-04-16 |
EP3679931A2 (en) | 2020-07-15 |
JP2014520072A (ja) | 2014-08-21 |
US20190209642A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013027554A2 (pt) | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CL2017002527A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015). | |
EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
BR112014010803A2 (pt) | método de tratamento | |
BR112014007357A2 (pt) | métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio | |
AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
EA201692506A2 (ru) | Ингибиторы репликации вирусов гриппа | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
MA32981B1 (fr) | Regime posologique pour un agoniste du recepteur s1p | |
BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112014021133A2 (pt) | composto; composição farmacêutica; método para tratar, administrar e/ou reduzir as doenças ou distúrbios, síndrome ou afecções associados à modulação de receptor de captação de cálcio; e processo para a preparação de composto | |
BRPI0907220A2 (pt) | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf | |
BR112014011223A2 (pt) | método de tratar uma doença proliferativa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |